(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 August 2013 (22.08.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/121228 A1

(51) International Patent Classification:
C12N 9/22 (2006.01) *C12Q 1/68* (2006.01)
C12N 9/99 (2006.01)

(21) International Application Number:
PCT/GB2013/050387

(22) International Filing Date:
18 February 2013 (18.02.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1202768.6 17 February 2012 (17.02.2012) GB
1216029.7 7 September 2012 (07.09.2012) GB

(71) Applicant: **BIOTEC PHARMACON ASA** [NO/NO]; Sykehusveien 23, N-9294 Tromsø (NO).

(71) Applicant *(for BB only)*: **GARDNER, Rebecca** [GB/GB]; Dehns, St Bride's House, 10 Salisbury Square, London Greater London EC4Y 8JD (GB).

(72) Inventors: **LANES, Olav**; Kveldrovegen 12, N-9007 Tromsø (NO). **HAVDALEN, Linda**; Skippergata 21B, N-9008 Tromsø (NO). **SOLSTAD, Terese**; Ringselveien 10, N-9100 Kvaløysletta (NO). **LORENTZEN, Marit**; Skyt-terstien 3b, N-9022 Krokelvdalen (NO).

(74) Agent: **GARDNER, REBECCA**; Dehns, St Bride's House, 10 Salisbury Square, London Greater London EC4Y 8JD (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ENDONUCLEASES

Figure 6a



(57) Abstract: The present invention provides an endonuclease I or enzymatically active fragment thereof wherein said endonuclease I has the sequence of SEQ ID No. 4 or a sequence which is at least 70% identical thereto and wherein the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif has been substituted with a residue which is negatively charged as well as nucleic acid molecules encoding these enzymes and methods of removing contaminating polynucleotides from a sample using these enzyme.

WO 2013/121228 A1

Endonucleases

The present invention relates to endonucleases that are inactivated by gentle treatment conditions, in particular showing thermolabile properties. The invention also comprises the removal of contaminating polynucleotides from a biological preparation through the use of such an endonuclease. The invention also relates to the prevention of false positive results in nucleic acid amplification reactions through the use of an endonuclease, in particular amplification reactions which involves a polymerase chain reaction (PCR) set-up.

Nucleic acids, and especially genomic DNA, often poses a problem in cell cultures, cell lysates and protein purification and analysis as it creates viscosity in the sample or interferes with purification, downstream analysis or applications. Removal of DNA and nucleic acid can be done physically, chemically or enzymatically. Enzymatic removal of DNA and RNA can be achieved by adding nucleases. However, nucleases often fail to degrade DNA in complex biological samples, because DNA is bound to proteins or other molecules protecting it from enzymatic degradation. Sodium chloride is often added to typical cell lysis buffers to limit protein-DNA interactions, and thus facilitate the removal of DNA in downstream protein purification. Unfortunately most nucleases become highly inhibited or inactive at moderate salt concentrations, often making enzymatic removal inefficient. Thus, removing all traces of DNA from proteins, reagents or biological samples is often troublesome.

Several commercial alternatives exists to enzymatically remove nucleic acids in cell lysates, protein purification and before analytical steps, such as Benzonase (*Serratia marcescens* nuclease), Omnicleave (Epicentre) or DNaseI. However, there is no option that can be inactivated by moderate heat-treatment. To remove the above enzyme after use, various resins, inhibitors or column purification steps are typically needed. This makes an enzymatic method more troublesome to use since an additional reagent or purification step is needed to remove the nuclease after use. This is more time consuming and may lead to lower yield of the protein of interest.

Problems with removing traces of DNA in protein purification or from reagents are evident in the endogenous DNA often found in commercial polymerases and master mixes. Furthermore, reagents for molecular biology applications (e.g. PCR and sequencing) and molecular diagnostics have to be free of both contaminating DNA and nucleases. The difficulties associated with removing the nucleases

described above after use make them less suitable to clean up reagents used for DNA technologies.

Nucleic acid amplification techniques such as PCR's are one of the most powerful tools available in biotechnology, allowing preparation of a large number of copies of a target sequence from a sample containing only a small amount of nucleic acid. In the case of PCR, oligonucleotide primers complementary to their respective strands of a double stranded target sequence are added to the reaction mixture containing the target sequence and free nucleotides. Thermal cycling in the presence of a DNA polymerase results in amplification of the sequence between the primers. The ability of the amplified fragments created by the PCR process to act as templates for subsequent PCR cycles results in the rapid production of a considerable quantity of the target sequence.

Amplification reactions of particular susceptibility to the detrimental effects of nucleic acid contamination are the quantitative PCR (qPCR) techniques, as these have the power to quantify less than 20 copies of a DNA sequence in a reaction. Thus, even the smallest levels of nucleic acid contamination can give false results in qPCR techniques. In addition, these methods require the detection of signals from the amplified target nucleic acids above an inevitable background signal. Contaminating nucleic acid can contribute to this background signal and so reduce the sensitivity of the technique. As such, minimising contaminating nucleic acid maximises the sensitivity of a quantitative PCR experiment. In experiments where small numbers of copies of target nucleic acids are detected, e.g. quantitative PCR-based pathogen diagnostics and pathogen load quantification, it is paramount that sensitivity of the quantitative PCR is maximised and false positives are minimised. In the field of bacteria identification and diagnostics where segments of highly conserved bacterial DNA are targeted (e.g. 16SrRNA or 23SrRNA genes) by qPCR techniques, nucleic acid contamination arising from the DNA polymerase preparation (which are typically obtained from bacteria and bacterial expression systems) is a major problem. Methods to remove bacterial nucleic acid contaminants efficiently from DNA polymerase preparations are therefore needed. Especially sought are methods that can achieve this without having a detrimental impact on downstream amplification reactions and without damaging the polymerase.

It has been suggested that individual PCR reaction mixtures can be treated prior to addition of the target DNA and *Taq* DNA polymerase using endonucleases that cut internal to the target sequence thus preventing amplification of contaminating DNA (Furrer *et al.* Nature. Vol. 346 page 324, 1990). This method requires a decontamination time of 30 minutes and in order to inactivate the endonuclease after

decontamination the reaction mixture is boiled. Because of this boiling step, it is necessary to add the DNA polymerase after decontamination. Of course, this represents a further risk of the introduction of carry-over into the pre-amplification mixture and decontamination of the DNA polymerase itself is precluded.

Thermolabile endonucleases that breakdown DNA specifically (DNases) have been described. WO 99/007887 discloses a DNase isolated from *Pandalus borealis* that is substantially irreversibly inactivated after 2 minutes at 94 °C. This same enzyme is also substantially irreversibly inactivated after 15 minutes at 65 °C. However, these temperatures are too high for certain applications and there is also a desire for removal of contaminating RNA and single stranded DNA (ssDNA).

Endonuclease I is a ≈ 25 kDa periplasmic or extracellular, monomeric enzyme known to cleave both RNA and DNA in a sequence independent manner. It is found in many different Proteobacteria and in Fibrobacter. The structure has a mixed alpha/beta topology containing nine beta strands, five short helixes and five long ones. It is able to cleave plasmids and ssDNA. It cleaves at the 3' side of the phosphodiester bond.

Endonucleases that are thermolabile have been described in the art by Altermark *et al* (FEBS Journal; 2007, 274: 252 to 263). They describe the endonuclease I isolated from the psychrophilic bacterium *Vibrio salmonicida* (VsEndA, SEQ ID NO: 1). This enzyme was found to have an enzymatic activity of less than 20% activity (compared to the optimum activity of this enzyme) at a temperature of 50 °C, compared to almost 100% activity under the same conditions found in the endonuclease I isolated from the mesophilic bacterium *Vibrio cholerae* (VcEndA, SEQ ID NO: 3). Moreover, the rate of irreversible unfolding at 70 °C was higher for VsEndA than for VcEndA.

It has been reported that the VsEndA and VcEndA described above are enzymatically more active in solutions of high salinity, due to the mildly halophilic characteristics of the bacteria *V. salmonicida* and *V. cholerae*. Niiranen *et al* (FEBS Journal; 2008, 275: 1593 to 1605) show that the catalytic constant (k_{cat}) peaks at a salt concentration of 0.25 M and 0.5 M for the VcEndA and VsEndA enzymes respectively.

An endonuclease which can be inactivated at mild temperatures and that does not detrimentally affect the activity of the protein, or other molecule of interest in the preparation, would provide a highly effective and efficient method for removing contaminating polynucleotides from a biological preparation. Ideally, this endonuclease would also be able to tolerate preparations containing a high level of salinity, because sodium chloride is often added to preparations in order to limit DNA-

protein interactions and produce a purer protein sample after the addition of the endonuclease. However, there is no endonuclease currently available with these properties.

Inactivation of the nuclease which is not reversed by changes in temperature is especially important for preparations that are to be used in further methods that may be performed at room temperature, or include cycles with a room temperature component. Simple thermolability, i.e. unfolding at a lower temperature than existing enzymes, is insufficient. Inactivation under mild conditions, e.g. low temperatures, needs to be combined with a reasonable yield of correctly folded protein on initial synthesis in order to provide a useful enzyme.

The present inventors have surprisingly found that a single point mutation in the amino acid sequence of the VsEndA enzyme, results in an enzyme that remains enzymatically active, even in preparations of high salinity, and yet can be inactivated under mild conditions. The residue whose substitution results in an enzyme with surprising and advantageous properties is a serine residue found in position 44. This serine residue resides immediately N-terminal of a highly conserved pentapeptide motif (Phenylalanine-Tyrosine-Cysteine-Glycine-Cysteine, or Phe-Tyr-Cys-Gly-Cys, or FYCGC). The sequence of wild type (wt) VsEndA is represented by SEQ ID NO: 1 and shown in Fig. 1. The numbering (44) includes an N terminal signal peptide which is cleaved during transport from cytoplasm to periplasm. The signal sequence is not shown in Figs 3 and 4 and the numbering in those figures is adjusted accordingly.

From the findings of Altermark *et al* (Biological Crystallography; 2006, D62, 1387 to 1391) it has been determined that this serine residue forms part of a complex with a buried chloride ion. This serine residue can be found in varying positions depending on the species of bacteria that the endonuclease I enzyme is derived from (for example, the equivalent serine residue in VcEndA is found at position 42, and the equivalent serine residue in the endonuclease I derived from *V. vulnificus* is found at position 41). From studying the sequences of the endonucleases derived from various bacteria of the *Vibrio* genus, it has been found that the amino acid that interacts with the chloride ion at the 40 to 50 sequence position is not always a serine. In the endonuclease derived from *V. furnissii*, for example, the equivalent amino acid is a threonine.

The present inventors have found that the replacement of this serine residue with a negatively charged or another polar residue leads to an enzyme that has the above properties.

Thus, according to the present invention, there is provided an endonuclease I or an enzymatically active fragment thereof, said endonuclease I having the sequence of SEQ ID No. 1 or a sequence which is at least 60% identical thereto, but wherein the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif has been substituted with a residue which is either negatively charged or polar, said endonuclease I or enzymatically active fragment thereof being substantially (irreversibly) inactivated when incubated at 30 °C for 15 minutes in the presence of 10 mM dithiothreitol (DTT).

Alternatively, the present invention provides an endonuclease I or an enzymatically active fragment thereof, said endonuclease I having the sequence of SEQ ID No. 1 or a sequence which is at least 60% identical thereto, but wherein the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif has been substituted with a residue which is either negatively charged or polar, wherein said endonuclease I or enzymatically active fragment is substantially (irreversibly) inactivated when incubated at 4 °C for 6 hours in the presence of either 10 mM DTT or 10 mM Tris(2-Carboxyethyl) phosphine (TCEP). It is appreciated that appropriate inactivation conditions are a reflection of temperature, time of incubation and a concentration of any added chemical destabilisers. The above conditions provide tests which define the enzymes of the invention and further sets of conditions and complete assay protocols are described in the Examples.

Alternatively viewed, the present invention provides, for the first time, an endonuclease I or an enzymatically active fragment thereof which is substantially (irreversibly) inactivated when incubated at 30 °C for 15 minutes in the presence of 10 mM DTT, or when incubated at 4 °C for 6 hours in the presence of either 10 mM DTT or 10 mM TCEP.

Thus, while the conditions which provide inactivation may vary, the nature of the preferred substitution is the same and thus, alternatively viewed, the invention provides an endonuclease I or an enzymatically active fragment thereof which is at least 70%, preferably at least 80%, 90%, 95% or 98%, identical to SEQ ID No. 1 or 4, but wherein the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif has been substituted with a residue which is either negatively charged or polar.

The negatively charged or polar residue may be either genetically coded or non-genetically coded. Preferably the introduced amino acid is negatively charged. Polarity and charge in the context of amino acids and in particular their side chain functional groups are well understood in the art and are typically assessed under normal physiological conditions.

By "substitution" of the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif, it is meant that this residue is replaced by a different amino acid, typically genetically encoded, but possibly a non-genetically coded amino acid or amino acid derivative. Preferably the residue, which is typically serine, is replaced by a negatively charged amino acid, such as glutamic acid or aspartic acid, or another polar amino acid, such as threonine, asparagine or glutamine. Alternatively, said amino acid residue is replaced with a non-genetically amino acid that is either negatively charged or polar. Preferred non-genetically coded amino acids are glutamic acid derivatives such as 4-Fluoro-DL-glutamic acid, γ-Carboxy-DL-glutamic acid and D-2-Aminoadipic acid. In the most preferred embodiment, the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif is replaced with glutamic acid.

In a preferred embodiment, the endonuclease I or enzymatically fragment of the invention is substantially inactivated when incubated for 30 minutes at 50 °C in the presence of 0.5 mM TCEP and residual activity is assessed in the presence of 0.5 mM TCEP; preferably the endonuclease I or enzymatically active fragment thereof is irreversibly inactivated under these conditions.

In a further aspect, the invention comprises a method of removing contaminating polynucleotides from a sample which comprises use of the endonuclease described above. The method will typically comprise contacting the sample with an endonuclease as defined above.

In a preferred embodiment, the sample is a preparation containing a protein of interest, for example a recombinantly produced protein of interest, e.g. an enzyme. Alternatively the protein of interest may be an analyte or other protein which it is desired to purify from a starting material. The preparation may be or be derived from a cell lysate or tissue sample or body fluid.

The protein of interest may be an antibody or antibody fragment. The protein (e.g. antibody) could be useful in diagnostic or therapeutic methods. Thus, the method above described may be used in order to ensure that the diagnostic or therapeutic protein is free from contaminating polynucleotides so that it may be safe to administer.

The protein of interest may be a DNA binding protein or other protein which associates with nucleic acid in solution. In particular, such proteins for which salt may conveniently be used to separate the protein of interest from the nucleic acid, given the observed ability of the endonuclease of the invention to function in the presence of salt.

The endonuclease of the invention may be particularly effective at salt (for example sodium chloride or potassium chloride) concentrations of 50 mM to 1 M, preferably about 500 mM. Many nucleases are inhibited at the high sodium chloride concentrations typically added to cell lysis and purification buffers and the salt tolerance of the endonucleases of the present invention is a particular advantage. Preferably, the endonucleases of the present invention have an optimum catalytic activity (as assessed herein) at 0.5 M sodium chloride or potassium chloride or an activity at this salt concentration which is no less than 60%, preferably no less than 75% of that exhibited at the optimum salt concentration. The "optimum salt concentration" is the concentration of sodium chloride at which the enzyme has its highest catalytic activity. Alternatively viewed, the endonucleases of the invention have an optimum catalytic activity when the concentration of sodium chloride is 0.35 to 0.65 M, preferably 0.45 to 0.55 M, more preferably around 0.5 M.

In another embodiment, the biological preparation is a reagent solution, e.g. that is used in a polynucleotide analysis technique, such as PCR, DNA/RNA sequencing or microarrays. The reagent solution may comprise or consist of a non-protein component or mixture, such as a PCR master mix or a buffer solution. The endonuclease described above could be used to remove any polynucleotide contamination from the reagent, be deactivated, and then said reagent be applied to a sample containing polynucleotide of interest, thus reducing the likelihood of contamination being introduced to a sample through the addition of said reagent.

The invention has utility in preventing or limiting contamination with polynucleotides and in particular in preventing or reducing false positive results and reducing background (positive No-template controls) due to endogenous polynucleotides in amplification reagents and enzymes.

The endonucleases of the invention are suitable for use in the elimination or reduction of endogenous DNA in amplification reactions. This is because the lower the inactivation temperature of the endonuclease the easier it is to inactivate it during the amplification process and the greater the degree of inactivation that can be achieved at any given temperature used in the inactivation step.

The endonuclease of the invention is thus used to degrade non-target polynucleotides present in the amplification reaction mixture or the individual components thereof, e.g. a polymerase. Thereby, non-specific amplification may be reduced or avoided.

As the endonuclease of the invention can be inactivated at low temperatures, in one preferred embodiment, the endonuclease is used to remove contaminating polynucleotides from a solution containing a protein or reagent of interest, wherein

said protein or reagent is itself thermolabile at temperatures above 37 °C (the temperature at which the endonuclease is enzymatically active).

Inactivation of the endonuclease of the invention will typically comprise incubation of the endonuclease with an inactivation additive. The inactivation additive destabilises the endonuclease, i.e. renders it more susceptible to unfolding at a given temperature. Endonuclease I contains a coordinated Mg^{2+} and multiple disulphide bonds and the skilled man will be aware of agents which can target these or other properties of the enzyme to destabilise it.

Because of the coordinated Mg^{2+} ion within the endonuclease, the concentration of Mg^{2+} ions may be of importance in the activity of the endonuclease. For this reason, a concentration of Mg^{2+} or Mn^{2+} ions of between 1 to 20 mM, preferably 5 to 10 mM, may be used in the methods of the invention. A PCR or protein purification buffer typically has a Mg^{2+} ion concentration of 5 mM in the form of magnesium chloride.

The inactivation additive may be a metal ion chelating agent, such as ethylenediaminetetraacetic acid (EDTA). The inactivation additive may also be a disulphide bond reducing agent (i.e. an agent that inhibits and/or disrupts disulphide bonds between two or more cysteine residues in a protein). Examples of such agents include, but are not limited to DTT, 2-mercaptoethanol (also known as β-mercaptoethanol), 2-mercaptoethylamine·HCl, TCEP (Tris(2-Carboxyethyl) phosphine) and N-ethylmaleimide. TCEP and DTT are preferred, TCEP is especially preferred. The skilled man would be able to determine the appropriate concentrations of disulphide bond reducing agent for his needs that would improve inactivation but would not be detrimental to his downstream reactions. For instance, DTT can conveniently be incorporated into the inactivation step at a concentration of between 0.05 and 50 mM.

Preferably, inactivation of the endonuclease in the methods of the invention occurs at a concentration of inactivation additive (e.g. DTT) of between 0.5 and 50 mM, more preferably between 1 and 20 mM, e.g. 5-20 mM.

Thus preferably inactivation additive is present at a concentration of at least 1 mM.

As shown in the Examples, the conditions required for inactivation represent a flexible combination of incubation temperature and time and inactivation additive concentration. Thus, inactivation may be achieved at 40 °C with 1 mM TCEP after 5-10 minutes of incubation, or at 30 °C with 10 mM DTT for 15 minutes. It will be apparent to the skilled man, depending on the nature of the biological preparation to be treated and on the subsequent uses thereof, which combination of conditions is

appropriate. The endonucleases of the invention are thermolabile but it should be appreciated from the foregoing that it may not be necessary to heat the enzyme in order to inactivate it.

Thus, in a further aspect, the present invention provides a method of removing nucleic acid (contamination) from a sample which comprises contacting the sample with an endonuclease of the invention under conditions which permit digestion of any polynucleotide therein and then contacting said sample and endonuclease mixture with an inactivation additive at a temperature and for a time sufficient to inactivate said endonuclease.

The two contacting steps will typically be incubations and are described herein, in particular in the Examples. Suitable incubation conditions to achieve digestion of nucleic acids in the sample are known in the art and may conveniently comprise incubation at 10-50 °C, e.g. at or around 35-37 °C for 5-30 minutes, e.g. 10-20 minutes, preferably around 15 minutes.

As described elsewhere herein, the incubation conditions for inactivation can vary considerably, at temperatures below 10 °C incubation may be for 1-24 hours, at temperatures from 10-30 °C incubation may be for 10 minutes to 2 hours and at temperatures above 30 °C, (for example 30-70 °C, more preferably 40 °C), incubation will typically be for 5-30 minutes. As shown in the Examples herein, the concentration and choice of inactivation additive will also affect the incubation times/temperature. Inactivation additives will preferably be used at the aforementioned low incubation temperatures.

Alternatively viewed, this aspect of the invention provides use of the endonuclease of the invention in removing nucleic acid contamination from an amplification reaction mixture or reagent.

In a further aspect the invention also provides a method of preventing or reducing false positive results due to carry-over in nucleic acid amplification reactions, said method comprising using the endonuclease of the invention to degrade carried-over non-target polynucleotides present in the amplification reaction mixture, or the individual components thereof.

The endonuclease of the present invention can also be used to remove nucleic acid contaminants from DNA polymerase preparations as well as being used to remove nucleic acid contaminants from amplification reaction mixtures comprising a DNA polymerase. The low inactivation temperature of the endonuclease of the present invention means that the inactivation of the endonuclease after decontamination can be achieved without a detrimental impact on the polymerase.

The term "nucleic acid amplification reaction" refers to any *in vitro* means for increasing the number of copies of a target sequence of nucleic acid. Preferably, methods will involve "thermal cycling", i.e. involving high temperature cycling. Amplification methods include, but are not limited to, PCR and modifications thereto, 3SR, SDA, LAR or LCR and LAMP and modifications thereto. PCR, LAMP and LCR and their modifications are thermal cycling methods. Methods may result in a linear or exponential increase in the number of copies of the target sequence. "Modifications" encompass, but are not limited to, real-time amplification, quantitative and semi-quantitative amplification, competitive amplification, and so on.

The target nucleic acid may be DNA or RNA depending on the selected amplification method. For example, for PCR the target is DNA, although when combined with a reverse transcription step the target can be considered to be an RNA sequence. 3SR amplifies RNA target sequences directly.

The term "amplification reaction mixture" refers to any solution, generally aqueous, comprising the various reagents used to amplify a target nucleic acid. These include enzymes, aqueous buffers, salts and nucleoside triphosphates. The term refers to mixtures which contain all the necessary components for carrying out a successful amplification reaction and to mixtures which are incomplete and therefore contain only some (e.g. at least 2, 3 or 4) of the required components. If prefaced by the term "complete" the reaction mixture contains all of the components necessary for amplification.

The term "carry over" is used to describe any nucleic acid which is accidentally or unintentionally introduced into a reaction mixture, in particular target sequences carried over from previous amplification reactions.

The term "false positive result" refers to a result which appears to show that the nucleic acid sample under investigation contains the target sequence but wherein the amplified product is derived from carry-over. Clearly, the reduction in contaminating DNA which the invention provides is particularly advantageous in the forensic and diagnostic fields. The methods of the invention enable the specificity and sensitivity of nucleic acid amplification to be increased.

The term "endonuclease" refers to an enzyme which hydrolyzes a phosphodiester bond in the polynucleotide backbone and is not nucleotide sequence specific. The "endonuclease I" of the present invention can cleave ds and ss polynucleotides, DNA and RNA.

The term "polynucleotide" refers to any chain of nucleotides. These polynucleotides can be RNA or DNA, and can be either double stranded or single stranded. The strands may also be either linear or super-coiled.

The term "salt" refers to any ionic compound that results from the neutralisation reaction of an acid and a base. Salts that are of interest are those that are commonly used to limit DNA-protein interactions and produce a purer protein sample after the addition of an endonuclease, and the skilled person would be aware of these salts. Salts or particular importance are sodium chloride and potassium chloride.

By "substantially inactivated" is meant that the enzyme is at least 95% inactivated, preferably 98% inactivated, more preferably the enzyme is 100% inactivated. Percentage inactivation can be conveniently measured by incubating a DNA sample (e.g. 500 bp PCR product) for 3 hours either with an inactivated endonuclease or with a non-inactivated endonuclease in a suitable buffer (e.g. Tris, HEPES, PBS) at 37 °C; separating the reaction products on an ethidium bromide agarose gel by electrophoresis and measuring the relative intensities of fluorescence of the relevant DNA bands under UV light. Alternative methods could be devised by the skilled man to measure to relative activities of inactivated and non-inactivated endonucleases. For instance, relative changes in fluorescence of SYBR green containing DNA samples could be used. Further methods are the Kunitz assay (Kunitz, M; 1950, S. Gen Physiol, 33:363 and WO 2011/010094) and the modified Kunitz assay devised by Yamamoto (Yamamoto, M; 1971, Biochem Biophys Acta, 228:95 and WO 2011/010094). Suitable methods are described in the Examples herein.

The benefit of "irreversible" inactivation is that the catalytic function of the endonuclease cannot be regained by changes in temperature and therefore the treated sample, which may still contain the inactivated endonuclease, can be used in further processing or applications which involve contact with nucleic acid of interest without digestion of that nucleic acid. Thus, the endonuclease does not regain its activity and there is substantially no residual activity; specifically, less than 5%, preferably less than 2%, most preferably no detectable endonuclease activity remains. The enzymes of the invention are capable of such "irreversible" inactivation (conditions which provide such inactivation are described herein) and thus inactivation is preferably irreversible inactivation. Inactivation can be considered "irreversible" even if it is dependent on the continued presence of an inactivation additive, e.g. a metal ion chelating agent or reducing agent.

Inactivation, including heat change resistant ("irreversible") inactivation, may require the endonuclease to still be in contact with an inactivation additive, as defined above. Unless otherwise clear from the context, residual activities described herein assume the continued presence of an inactivation additive, e.g. at least 0.1,

preferably at least 0.2 mM of additive, e.g. TCEP; weaker reducing agents (e.g. DTT) may require higher concentrations, for example at least 0.5 or 1 mM. Typically no more than 10 mM, preferably no more than 5 mM is required or present.

For certain applications, it may be desirable to have an endonuclease I which is inactive even when no, or essentially no, inactivation additive is present. Methods for removal of inactivation agent are known in the art and include dialysis and the use of desalting or buffer exchange columns. The enzymes of the present invention, if treated appropriately, can be inactivated to this extent. Suitable conditions are described in Example 8. Appropriate conditions will depend on (i) the choice of inactivation additive used, (ii) the concentration of inactivation additive added to the endonuclease (iii) the inactivation temperature the endonuclease is heated to (in the presence of inactivation additive) (iv) the time at which the endonuclease is incubated at the inactivation temperature, (v) the temperature the endonuclease is stored at after cooling from the inactivation temperature (in the presence of the inactivation additive) and (vi) the time at which the endonuclease is incubated at the storage temperature.

The skilled man would appreciate that alterations to some of the parameters that favour inactivation, such as an increase in the concentration of the inactivation additive, may affect the other parameters, such as the time the endonuclease needs to be stored at the storage temperature in the presence of the inactivation additive, in order for irreversible inactivation to occur.

By way of example, the inventors have found that VsEndA_S44E may be rendered inactive even in the absence of inactivation agent when 10 mM TCEP is added, the endonuclease is heated to 50 °C for 60 minutes, followed by storage at room temperature for two days (the TCEP is then removed).

Alternatively, if 1 mM TCEP is added to the endonuclease and the endonuclease again heated to 50 °C for 60 minutes but the storage temperature increased to 37 °C, the storage time necessary for irreversible inactivation decreases to one day.

It is possible to achieve such inactivation without any initial increase in temperature. For example, for VsEndA_S44E inactivation may be achieved by storing it with 10 mM TCEP for one day at 37 °C or for four days at room temperature. In these cases, the inventors found that even when TCEP was removed by dialysis, the enzyme remained inactive.

The variation of inactivation conditions described above shows the flexibility that the endonucleases of the invention provide. If the sample of interest is known not to be affected by an inactivation additive, the skilled person may choose keep the

additive in the sample in order to reduce the inactivation time or temperature. On the other hand, if the skilled person wishes to remove the inactivation additive, he or she may incubate the sample with the inactivation additive for a longer period of time or apply an higher inactivation temperature.

Substantial inactivation preferably occurs within 15 minutes of incubation at a temperature of at or about 30 °C, e.g. 28 to 32 °C in the presence of an inactivation additive. The endonuclease of the invention may be substantially inactivated at lower temperatures or over shorter time periods but, in accordance with the invention, heating for about 15 minutes at about 30 °C in the presence of DTT is preferably sufficient to substantially inactivate the enzyme. It will be readily apparent to the skilled man that adjustments to one of these two parameters can be compensated for by adjusting the other. For instance increasing the inactivation temperature might permit the duration of incubation to be reduced. Conversely, increasing the duration of incubation might permit a lower inactivation temperature to be used. Of course, as is also readily apparent to the skilled man and shown in the Examples, when the endonuclease of the invention is used in the methods of the invention, durations of incubation longer than 15 minutes may be used and inactivation temperatures greater than about 30 °C may be used.

Inactivation temperatures and times for an endonuclease should be assessed by incubating the endonuclease in a solution that mimics a typical PCR or protein purification buffer (e.g. 25 mM Tris/HCl, pH 8.5, 5 mM $MgCl_2$). The endonuclease should be present at about between 0.1 U/µl and 100 U/µl, preferably between 1 and 50 U/µl, e.g. 25-30 U/µl. Suitable protocols are described in the Examples.

The reaction mixture is preferably at a pH that the sample or protein of interest is stable at. A pH of between 7.0 and 9.5, preferably around 8.5, is particularly suitable with regard to the enzymatic activity of the endonuclease of the invention. A pH of 8.5 would also suit a typical PCR or protein purification buffer.

Advantageously, the thermolabile endonuclease of the invention is fully functional in a complete amplification reaction mixture, and is compatible with standard *in vitro* amplification reactants and conditions. The enzyme should also be capable of removing suitable amounts of contaminating polynucleotides and/or carry-over from a reaction mixture, usually fg- or pg-levels but preferably up to 1 ng. Preferably, the endonuclease is able to degrade all the carry-over within 60 minutes at 37 °C, more preferably within 30 minutes, most preferably within 15 minutes.

Also included within the scope of the present invention are enzymatically active fragments of the endonucleases of the invention, it being appreciated that

catalytic activity can be retained in truncated and other variants. The Examples provide a suitable assay of endonuclease activity.

The present invention is exemplified by the preferred S44E mutation to VsEndA and more generally, modified versions of VsEndA are preferred embodiments of endonucleases of the present invention. The serine may be replaced by residues other than Glu(E), in particular by non-genetically coded homologues of Glu or by threonine, asparagine or glutamine. The residue equivalent to serine 44 in other endonuclease I sequences may be substituted. The residue equivalent to serine 44 in VsEndA is shown for other species in the sequence alignments of Figures 3 and 4. The following tables show the percentage sequence identity of various Vibrio species (Table 1) and a selection of other bacteria (Table 2) with SEQ ID No. 1 (VsEndA). The endonucleases in these tables and the corresponding figures are preferred endonucleases for modification according to the teaching of the present invention and the resulting enzymes are preferred endonucleases of the invention.

Sequence 1	**Sequence 2**	**% Identity**
V. salmonicida	*V. fischeri*	91
V. salmonicida	*V. wodanis*	91
V. salmonicida	*V. splendidus*	78
V. salmonicida	*V. cholerae*	71
V. salmonicida	*V. harveyi*	77
V. salmonicida	*V. rotiferianus*	77
V. salmonicida	*V. tubiashii*	73
V. salmonicida	*V. sinaloensis*	74
V. salmonicida	*V. vulnificus*	74
V. salmonicida	*V. furnissii*	70
V. salmonicida	*V. anguillarum*	71

Table 1

Sequence 1	Sequence 2	% Identity
V. salmonicida	*V. cholerae*	71
V. salmonicida	*Oceanimonas sp.*	64
V. salmonicida	*Salmonella sp.*	65
V. salmonicida	*Enterobacter sp.*	65
V. salmonicida	*Yokenella sp.*	66
V. salmonicida	*Klebsiella sp.*	65
V. salmonicida	*Escherichia coli*	65
V. salmonicida	*Shigella sp.*	64
V. salmonicida	*Citrobacter sp.*	66
V. salmonicida	*Cronobacter sp.*	68
V. salmonicida	*Rahnella sp.*	63
V. salmonicida	*Erwinia sp.*	62
V. salmonicida	*Yersinia sp.*	63
V. salmonicida	*Serratia sp.*	62
V. salmonicida	*Pseudomonas sp.*	51

Table 2

Preferably the endonuclease of the invention is a Vibrio endonuclease or derived therefrom. A further particularly preferred modified endonuclease according to the present invention is from *Vibrio cholerae* (VcEndA), e.g. in which the serine adjacent to the pentapeptide motif is replaced by glutamic acid.

Preferred endonucleases are those which lack the N terminal signal peptide, i.e. are represented by SEQ ID No. 4 or sequences which are at least 60%, preferably at least 70%, 80%, 90%, 95% or 98% identical to SEQ ID No. 4. As the mature endonuclease of the invention lacks the signal peptide, unless otherwise clear from the context, any reference herein to SEQ ID No. 1 can be considered also a reference to SEQ ID No. 4. SEQ ID No. 4 is the first sequence recited in both Figs. 3 and 4.

Preferred endonucleases of the invention have the sequence of SEQ ID Nos. 1, 3, 4 or 5 but wherein the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif has been substituted with a residue which is either negatively charged or polar, preferably negatively charged. Endonucleases of SEQ ID Nos. 1 or 4 in which the serine at position 44 has been replaced with glutamic acid are most preferred.

Further preferred endonucleases of the invention have a sequence of an endonuclease I obtainable from a Vibrio species but wherein the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif has been substituted with a residue which is either negatively charged or polar, preferably negatively charged.

As discussed herein, the amino acid replacing the residue N terminal of the identified pentapeptide motif should not be hydrophobic. The modified enzyme VsEndA_S44A (alanine) was prepared but the yield was only about 5% of that achieved with S44E and it was highly unstable, quickly losing all catalytic activity.

Percentage sequence identity according to the invention can be calculated using any of the widely available algorithms (e.g. using the Clustal W2 multiple sequence alignment program (http://www.ebi.ac.uk/Tools/clustalW2) using default parameters (DNA Gap Open Penalty = 15.0; DNA Gap Extension Penalty = 6.66; DNA Matrix = Identity; Protein Gap Open Penalty = 10.0; Protein Gap Extension Penalty = 0.2; Protein matrix = Gonnet; Protein/DNA ENDGAP = -1; Protein/DNA GAPDIST = 4)

The exact position of the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif (i.e. the polar residue that forms part of the complex with the chloride ion) in the endonucleases can be readily identified by using standard sequence alignment techniques such as Clustal W2 to produce alignments such as that represented in Figures 3 and 4. If a sequence lacks a fully conserved FYCGC motif it will still be possible using these techniques of sequence alignment to identify the residue equivalent to serine 44 in SEQ ID NO 1.

Nucleic acid molecules encoding the endonucleases of the invention and fragments thereof constitute a further aspect of the present invention, with SEQ ID NO:2 and sequences at least 80 or 90% identical thereto being preferred.

The invention also provides the use of the particular endonuclease described above as a decontaminating agent in methods of amplifying a nucleic acid. The use of the particular endonucleases described above in the decontamination methods described herein represents a particularly preferred embodiment of the invention.

A method for the isolation and purification of an endonuclease or an enzymatically active fragment thereof as described above represents a further aspect of the present invention. Thus, in this aspect the invention provides such a method, said method comprising expressing said endonuclease or fragment thereof in a suitable host cell (e.g. *Pichia pastoris; Escherichia coli; S. cereviciae,* baculovirus infected insect cells), and subsequently separating the endonuclease from said host cells and/or the media in which said cells have been cultured. Expression of said

endonuclease or fragment thereof can be achieved by incorporating into a suitable host cell an expression vector encoding said endonuclease or fragment thereof. Host cells comprising these expression cassettes and nucleic acid molecules are encompassed by the invention.

The endonuclease enzyme may be separated, or isolated, from the host cells/culture media using any of the purification techniques for protein known in the art and widely described in the literature or any combination thereof. Such techniques may include for example, precipitation, ultrafiltration, dialysis, various chromatographic techniques, e.g. gel filtration, ion-exchange chromatography, affinity chromatography, electrophoresis, centrifugation etc.

Likewise an extract of host cells may also be prepared using techniques well known in the art, e.g. homogenisation, freeze-thawing etc and from this extract the endonucleases of the invention can be purified.

It has been found that a purification protocol based on a combination of ion exchange chromatography and affinity chromatography, e.g. on a sepharose column, e.g. a Red sepharose (Pharmacia Biotech, Sweden) or a Blue sepharose (GE Healthcare) column, may readily be used to isolate the enzyme.

More particularly, the extract may be subjected to ion-exchange chromatography and the protein eluted with a NaCl gradient. The fractions containing endonuclease activity may be dialysed and then applied to an affinity column before final elution with NaCl.

The yields of the endonucleases of the invention are exceptionally good and thus, alternatively viewed, the invention provides a method of increasing the yield of a recombinantly expressed endonuclease I which comprises substituting the residue immediately N-terminal of the pentapeptide motif FYCGC with a residue which is either negatively charged or polar. Suitable endonucleases which may be modified in this way are described herein and exemplified e.g. in Figures 3 and 4. Suitable expression methods are described above.

The present invention also provides kits which comprise at least an endonuclease according to the invention. The kits may also contain some or all of the necessary reagents, buffers, enzymes etc. to carry out nucleic acid amplification reactions. More particularly, the kits may contain nucleotide triphosphates (including dATP containing an α thiol group (dATPαS) for strand displacement Amplification), oligonucleotide primers, preferably those capable of functioning at about 30 °C, DNA polymerases, preferably a thermostable polymerase such as *Taq* polymerase or Bst polymerase (and hot-start versions thereof) or, in the case of LAR, a DNA ligase (preferably a thermostable DNA ligase such as Ampligase® or that disclosed in US

6280998 which is isolated from *Pyrococcus furiosus*) or a restriction enzyme (preferably a thermostable restriction enzyme such as BsoB1). The endonuclease may be provided in one compartment together with a reverse transcriptase, DNA polymerase, strand displacement polymerase or LCR ligase.

Kits may contain written materials as guidance on how to perform procedures related to the invention. In particular guidance on inactivation conditions may be provided. Suitable conditions are described elsewhere herein but, by way of further general examples, which may also be provided with the kit or enzyme, Table 3 gives suggested incubation conditions in the presence of inactivation additive that are suitable for the inactivation of endonuclease derived from *Vibrio salmonicida* with the Ser44Glu mutation (VsEndA_S44E).

Temperature (°C)	**Concentration of Dithiothreitol (DTT) /Time**	**Concentration of Tris(2-Carboxyethyl)phosphine (TCEP) /Time**
25	20 mM/60 min	15 mM/60 min
40	10 mM/30 min	5 mM/30 min
50	1 mM/30 min or 10 mM/15 min	0.5 mM/30 min
60	1 mM/30 min	0.5 mM/30 min or 10 mM/15 min
65	1 mM/30 min	1 mM/30 min
70	1 mM/30 min	1 mM/30 min

Table 3

The present invention also provides compositions comprising an endonuclease of the invention and one or more of the necessary reagents to carry out nucleic acid amplification and methods, e.g. those components described above. Typically such compositions will be aqueous and buffered with a standard buffer such as Tris, HEPES, etc.

In a further aspect, the present invention provides a composition comprising an endonuclease I or active fragment as defined herein together with a second endonuclease I or enzymatically active fragment thereof. Preferably the second endonuclease I or enzymatically active fragment thereof has the sequence of SEQ ID No. 5 or a sequence which is at least 80% identical thereto. The second enzyme

may incorporate mutations, e.g. to the native *Vibrio cholerae* sequence which render it more readily inactivated. Such combinations allow the composition as a whole to provide effective endonuclease activity at a greater range of pH and/or salt concentration and/or temperature.

The invention will now be described by way of non-limiting Examples with reference to the following figures in which:

Fig. 1 shows the alignment of the amino acid sequences (including the signal peptide) of the endonucleases derived from *Vibrio salmonicida* (VsEndA) and *V. cholerae* EndA (VcEndA), SEQ ID NO:1 and SEQ ID NO:3 respectively.

Fig. 2 shows the nucleic acid sequence and the amino acid sequence (including the signal peptide) of VsEndA with the Ser44Glu mutation (VsEndA_S44E), SEQ ID NO:2 and SEQ ID NO:6 respectively.

Fig. 3 shows the sequence alignment data of the amino acid sequences (excluding the signal peptides) of wild type endonuclease I derived from bacteria from a variety of different genera.

Fig. 4 shows the sequence alignment data of the amino acid sequences (excluding the signal peptides) of wild type endonuclease I derived from various bacteria of the *Vibrio* genus.

Fig. 5 shows the expression levels of the VsEndA_S44E mutant (the VsEndA endonuclease with the Ser44Glu mutation) and the wild type VsEndA enzyme (SEQ ID NO: 1) in *Pichia pastoris* host cells containing the pPIC9K-VsEndA_S44E and the wild-type expression cassettes respectively.

Fig. 6 shows the rate of VsEndA and VsEndA_S44E inactivation at 40 °C (6a) and 50 °C (6b) both in the presence and absence of 1 mM DTT.

Fig. 7 shows the rate of VsEndA_S44E inactivation at 40 °C in the presence of 1 mM of one of the following inactivation additives: DTT, Tris(2-Carboxyethyl) phosphine (TCEP) and 2-mercaptoethanol.

Fig. 8 shows the photographs of agarose gels which show the activity of the endonuclease of VsEndA_S44E and the wild type VsEndA which have been inactivated in the presence of DTT at a concentration of either 1 mM, 10 mM or 20 mM for 15, 30 or 60 minutes at a temperature of either 50 °C (Fig. 8a), 40 °C (Fig. 8b), 30 °C (Fig. 8c) or 25 °C (Fig 8d). Results were compared against either no enzyme (negative control) or 6 U wild-type VsEndA (positive control).

Fig. 9 shows the photographs of agarose gels which show the activity of the endonuclease of VsEndA_S44E and the wild type VsEndA which have been incubated at 4 °C for either 6 or 18 hours in the presence of either DTT (Fig. 9a) or TCEP (Fig. 9b) at a concentration of either 1 mM, 10 mM or 20 mM. Results were

compared against either no enzyme (negative control) or 6 U wild-type VsEndA (positive control).

Fig. 10 shows the degree of removal of spiked DNA from the commercially available AccuStart™ Taq DNA polymerase (Fig. 9a) or GoTaq® Hot Start polymerase (Fig. 9b) using the VsEndA_S44E mutant.

Fig. 11 shows the degree of removal of spiked DNA from commercially available Maxima qPCR master mix using the VsEndA_S44E mutant.

Fig. 12 shows the degree of removal of spiked bacterial genomic DNA from commercially available TEMPase DNA polymerase using the VsEndA_S44E mutant in a solution containing either 0.5 M sodium chloride (Fig. 11a) or 1 M sodium chloride (Fig 11b).

Fig. 13 shows the degree of removal of spiked bacterial genomic DNA from an *E. coli* cell lysate solution containing a recombinantly expressed protein using the VsEndA_S44E mutant in varying sodium chloride solutions (0 M, 0.25 M, 0.5 M, 0.75 M and 1.0 M).

Fig. 14 shows the optimum activity of the VsEndA_S44E mutant in solutions with high salinity. The activity was tested in a 25 mM Tris-HCl buffer, pH 8.5, 5 mM magnesium chloride, with varying concentrations of sodium chloride and potassium chloride. The maximum activity obtained was set to 100%.

Fig. 15 shows the activity of the VsEndA_S44E mutant at varying temperatures. The activity was tested in a 25 mM Tris-HCl buffer, pH 8.5 containing 5 mM magnesium chloride and 0.5 M sodium chloride.

Fig. 16 shows the ability of the VsEndA_S44E mutant to degrade DNA at varying levels of pH and sodium chloride concentrations, as compared to commercially available Benzonase (*Serratia marcescens*) nuclease. Reactions were carried out at a pH of either 7.5, 8.0 or 8.5 and at a sodium chloride concentration of either 0.25 M or 0.5 M (Fig. 16a) or 0.75 M or 1.0 M (Fig. 16b). Reaction mixtures contained 100 µL Tris-HCl buffer with 5 mM magnesium chloride, 50 µg calf thymus DNA and 300 U of either VsEndA_S44E or Benzonase. Reaction mixtures were incubated at 37 °C for 30 minutes. The reactions were stopped using an EDTA-containing loading buffer and run on a 1% agarose gel.

Fig. 17 shows the ability of the VsEndA_S44E mutant to degrade DNA in *E. coli* lysates containing a DNA binding protein. VsEndA_S44E was added to *E. coli* lysates at varying sodium chloride concentrations and incubated at 37 °C for 30 minutes. Control contains no sodium chloride.

and in which

SEQ ID NO: 1 is the amino acid sequence of the translated portion of the cDNA nucleotide sequence of the wild-type *Vibrio salmonicida* endonuclease I, including the signal peptide.

SEQ ID NO: 2 is the cDNA nucleotide sequence of the mutant *Vibrio salmonicida* endonuclease I (VsEndA with the TCC to GAG mutation) including the signal sequence.

SEQ ID NO: 3 is the amino acid sequence of the translated portion of the cDNA nucleotide sequence of the wild-type *Vibrio cholera* endonuclease I, including the signal peptide.

SEQ ID NO: 4 is the amino acid sequence of the translated portion of the cDNA nucleotide sequence of the wild-type *Vibrio salmonicida* endonuclease I, without the signal peptide.

SEQ ID NO: 5 is the amino acid sequence of the translated portion of the cDNA nucleotide sequence of the wild-type *Vibrio cholera* endonuclease I, without the signal peptide.

SEQ ID NO: 6 is the amino acid sequence of the mutant *Vibrio salmonicida* endonuclease I (VsEndA, with a serine residue substituted for a glutamic and residue at position 44), including the signal sequence.

SEQ ID NO: 7 to SEQ ID NO: 20 are endonuclease I amino acid sequences, without signal peptide, derived from bacteria from a variety of different genera as described in Table 2 and Figure 3.

SEQ ID NO: 21 to SEQ ID NO; 30 are endonuclease I amino acid sequences, without signal peptide, derived from various bacteria of the Vibrio genus as described in Table 1 and Figure 4.

Examples

EXAMPLE 1 - Cloning and mutagenesis

The gene for *Vibrio salmonicida* endonuclease I was PCR amplified from a vector containing the gene and cloned into the pPIC9K expression vector for *Pichia pastoris*. The native signal sequence of *V. salmonicida* endonuclease I was omitted in the expression vector, such that the amino acid sequence of *V. salmonicida* endonuclease I following the α-mating factor encoded by the expression plasmid was APPSSF.

The *V. salmonicida* endonuclease I (VsEndA) was mutated at residue 44 from serine (Ser) to glutamic acid (Glu) using the QuikChange™ mutagenesis kit from Agilent following instructions from the manufacturer. The pPIC9K vector containing the truncated VsEndA sequence was used as a template. Correct sequence after mutagenesis reactions was verified by DNA-sequencing.

EXAMPLE 2 - Expression and purification

The pPIC9K-VsEndA_S44E vector was linearized using SacI and transformed into *Pichia pastoris* GS115 as described in the manual for the *Pichia pastoris* expression Kit (Life Technologies). The *V. salmonicida* S44E_endonuclease I (VsEndA_S44E) was expressed in shake flasks essentially as described in the *Pichia* expression kit. A 50 ml preculture of the GS115 strain containing the VsEndA_S44E in BMGY medium was cultivated overnight at 30°C. The cells were centrifuged and resuspended in 250 ml BMMY and expression was done for 72 h at 20°C. Addition of methanol to a final concentration of 0.5% was done every 24 h. The cells were removed by centrifugation and the supernatant was used as a starting material for purification. The VsEndA_S44E was purified using cationic exchange chromatography. The supernatant (250 ml) was applied on a SP-Sepharose FF (1.6/3) column equilibrated in 25 mM Tris/HCl, pH 8.3, 5 mM $MgCl_2$ using a flow of 5 cm/min. The column was washed with 250 ml of 0.4 M NaCl in the above buffer. Elution of the VsEndA_S44E was done using 25 mM Tris/HCl, pH 8.3, 5 mM $MgCl_2$ + 1M NaCl. Fractions containing VsEndA_S44E activity were pooled and finally concentrated.

EXAMPLE 3 - Measurement of nuclease activity

Nuclease activity may be assayed according to the procedure of Kunitz (Kunitz, M., 1950, Crystalline Deoxyribonuclease, II, Digestion of Thymus Nucleic Acid. The Kinetics of Reaction. J. Gen. Physiol., **33**, 363-377). A modified composition of this has been used to measure nuclease activity. Ten µl of enzyme preparation is added to 50 µg calf thymus DNA in 25 mM Tris/HCl, pH 8.5, 0.5 M NaCl, 5 mM $MgCl_2$, in a final volume of 1 ml. The mixture is incubated at 37 °C and increase in absorption is measured at 260 nm. 1 U = 0.01 OD_{260} increase × min^{-1}.

A study was carried out whereby the activity of the VsEndA_S44E mutant was assessed at various temperature (with no reducing agent present). Figure 15 shows that VsEndA_S44E has optimum activity at about 35°C, but works over a broad temperature range (20% activity at 10°C and 50°C).

EXAMPLE 4 - Comparison of expression level of VsEndA_S44E v wild-type (VsEndA)

A 50 ml preculture of the GS115 strain containing the pPIC9K-VsEndA_S44E expression cassette was compared to a strain containing the wild type expression cassette. The two strains were cultivated overnight at 30°C in BGMY medium. The cells were centrifuged and resuspended in 250 ml BMMY and expression was done for 72 h at 20°C. Addition of methanol to a final concentration of 0.5% was done each 24 h and nuclease activity was measured as described.

Figure 5 shows that the VsEndA_S44E mutant gives a higher expression level in *Pichia pastoris* than the wild-type VsEndA enzyme in terms of active expressed enzyme measured in U/ml in the cell-supernatant. The VsEndA_S44E mutant has been shortened to "S44E" and the wild-type VsEndA to "wt" in the Figure legends.

After purification as described above (in Example 2), the specific activity of VsEndA_S44E is determined to be about 20% higher than the VsEndA, as shown in Table 4.

Table 4

Endonuclease	Activity (U/ml)	Protein concentration (mg/ml)	Specific activity (U/mg)
VsEndA_S44E	1.69×10^7	0.69	2.4×10^7
VsEndA	1.12×10^7	0.56	2.0×10^7

EXAMPLE 5 - Temperature stability of VsEndA_S44E compared to VsEndA

The half-life of the wild-type (VsEndA) enzyme is approximately 2h at 70°C and 5h at 60 °C (data not shown).

Enzymes, VsEndA_S44E and VsEndA, were diluted to a concentration of 200,000 U/ml in a buffer containing 25 mM Tris/HCl, pH 8, 5 mM $MgCl_2$, 150 mM NaCl, 0.01 % Triton X-100, and ± 1 mM dithiothreitol (DTT). A volume of 6 x 100 µl was transferred to different eppendorf tubes. The samples were incubated at 40 °C or 50 °C for 0 to 40 minutes and thereafter placed on ice sequentially. The remaining activity was measured using the modified Kunitz assay as described in Example 3. From the data shown in Figure 6, it is evident that for both VsEndA_S44E and VsEndA, the addition of DTT is required for heat-inactivation. Upon addition of DTT the enzymes inactivate at a faster rate. The VsEndA_S44E mutant has been shortened to "S44E" and the wild-type VsEndA to "wt" in the Figure legends.

EXAMPLE 6 - Temperature inactivation using different reducing agents

The ability of VsEndA_S44E to be inactivated using a range of inactivation additives comprising DTT, Tris(2-Carboxyethyl) phosphine (TCEP) and 2-mercaptoethanol was tested at a temperature of 40 °C.

When comparing the data shown in Figure 7 with that of Figure 6a, it can be determined that all of the inactivation additives facilitated inactivation. DTT and TCEP were found to be more effective as inactivation additives compared to 2-mercaptoethanol. The VsEndA_S44E mutant has been shortened to "S44E" and the wild-type VsEndA to "wt" in the Figure legends.

EXAMPLE 7 - Heat inactivation experiments

To examine the temperature stability and to determine if it is possible to completely inactivate the VsEndA_S44E using heat, the integrity of a purified PCR-product in the presence of the heat-inactivated enzyme was assessed. This provided a more sensitive assay compared to the modified Kunitz assay described in Example 3, as it can test whether the inactivation is reversible upon decrease in temperature, or irreversible.

Enzyme (VsEndA_S44E or wild-type, VsEndA, 130U/µl) in a 25 mM Tris/HCl pH 8.5, 0.5M NaCl, 5 mM $MgCl_2$ buffer was transferred to Eppendorf tubes in a total volume of 50 µl. Freshly made Dithiothreitol (DTT) were added to a final concentration of 1, 10 or 20 mM. Samples were heat inactivated for 15, 30 or 60 minutes at various temperatures. Tubes were placed on ice after the inactivation step.

Assay for determination of residual activity was performed by adding 5 µl of heat-inactivated enzyme to 500 ng of a 500 bp PCR-product in a buffer consisting of 25 mM Tris/HCl pH 8.5, 5 mM $MgCl_2$ and 0.5 M NaCl. Samples were incubated for 3 hours at 37 °C. Where DTT was added to the enzyme preparation for inactivation, it was also present in the assay for residual activity.

Finally, to determine any degradation of the PCR-product, samples were analyzed on 1 % agarose gel. A negative control (no enzyme) and a positive control (containing 6U wt-enzyme) were treated in the same way as in the reactions above.

Figure 8 summarise the heat-inactivation experiments of the VsEndA_S44E mutant compared to the wild type VsEndA enzyme at 50 °C, 40 °C, 30 °C and 25 °C. The negative control shows the intact PCR-product, whereas the positive control illustrates the effect of approximately 1 % residual activity. At 50 °C, the VsEndA_S44E mutant enzyme was found to be completely inactivated after 15 minutes in the presence of 1 mM DTT, while the wild-type was only partially inactivated. At 40 °C, 1 mM DTT was able to partially inactivate the VsEndA_S44E mutant after 15 minutes, compared to the 10 mM required to partially inactivate the VsEndA enzyme. At 25 °C, DTT at a concentration of 20 mM or less was not able to fully inactivate the VsEndA enzyme after 60 minutes, whereas 10 mM of DTT was able to fully inactivate the VsEndA_S44E mutant after 60 minutes, demonstrating the effect of the substitution. The addition of at least 10 mM DTT is necessary for

complete inactivation of the VsEndA_S44E mutant enzyme at 30 °C. The VsEndA_S44E mutant has been shortened to "S44E" and the wild-type VsEndA to "wt" in the Figure legends.

In a further heat-inactivation experiment, the VsEndA_S44E mutant compared to the wild type VsEndA enzyme at 4 °C, in the presence of either DTT or TCEP at a concentration of either 1 mM, 10 mM or 20 mM, using the same controls described above. As shown in Figure 9, even at this low temperature, the presence of 10 mM DTT or TCEP was able to completely inactivate the VsEndA_S44E mutant after 6 hours. In comparison, even 20 mM DTT was not able to inactivate the wild type VsEndA enzyme after 18 hours of incubation. TCEP was shown to completely inactivate the VsEndA enzyme at this temperature either after 18 hours of incubation at a concentration of 10 mM or more or after 6 hours of incubation at a concentration of 20 mM.

EXAMPLE 8 - Heat inactivation experiments - Residual Activity in the absence of TCEP

In this Example, we determined the conditions where inactivation of VsEndA_S44E is still observed after the removal of the inactivation additive.

This Example was carried out in a similar manner to Example 7 except that the inactivation additive TCEP was studied, and, after inactivation had taken place, the TCEP was removed by dialysis using Pur-A-Lyzer dialysis tubes (Sigma). The buffer was exchanged once during a two-day dialysis. Determination of residual activity was performed using a 1% agarose gel as described in Example 7.

A selection of optimal inactivation parameters determined from this study are presented in Table 5.

Parameter				
(i) (mM)	(ii) (°C)	(iii) (min)	(iv) (°C)	(v) (days)
10	50	60	RT	2
10	N/A	N/A	37	1
10	N/A	N/A	RT	4
1	50	60	37	1

Table 5 - Parameters required to achieve inactivation in VsEndA_S44E. Parameter (i) - concentration of the inactivation additive TCEP added to the endonuclease (mM), parameter (ii) - the inactivation temperature the endonuclease is heated to (in the presence of inactivation additive) (°C), parameter (iii) - the time at which the endonuclease is incubated at the inactivation temperature (minutes), parameter (iv) - the temperature the endonuclease is stored at after cooling from the inactivation temperature (in the presence of the inactivation additive) (°C or "RT" for room temperature) and parameter (v) the time at which the endonuclease is incubated at the storage temperature (days). "N/A" for parameters (ii) and (iii) apply when VsEndA_S44E is not heated to an inactivation temperature.

EXAMPLE 9 - Removal of contaminating DNA from a DNA polymerase preparation

The ability of VsEndA_S44E to remove contaminating bacterial genomic DNA from commercial DNA polymerases in a typical polymerase buffer was tested. 0.14 U/µL Accustart (Quanta Biosciences), Tempase (VWR) or GoTaq (Promega) was treated with 28 U/µL VsEndA_S44E for 15 minutes at 37°C in a buffer consisting of 10 mM Tris-HCl, 111 mM KCl, 5.6 mM $MgCl_2$. After incubation at 37°C for 15 minutes, DTT was added to a final concentration of 10 mM and the samples were incubated at 40°C for 30 minutes in order to inactivate the VsEndA_S44E mutant. Finally primers, probes and dNTPs were added and the final concentration of the components in the polymerase reaction mixture was: 25 mU/µL DNA polymerase, 300 nM of each primer, 200 nM probe, 100 µM dATP, dCTP, dGTP and 200 µM dUTP in a buffer composed of 10 mM Tris-HCl, 20 mM KCl, 5 mM $MgCl_2$.

The following controls were included: a) samples containing buffer instead of VsEndA_S44E, b) samples containing buffer and *E. coli* genomic DNA, c) samples where *E. coli* genomic DNA was added before VsEndA_S44E inactivation, and d)

samples where *E. coli* genomic DNA was added after VsEndA_S44E inactivation. The qPCR was performed in 20 µl reactions in a Stratagene Mx3500P (Agilent technologies) and the thermal cycling conditions were as recommended by the manufacturers of the DNA polymerases.

VsEndA_S44E was able to remove contaminating bacterial genomic DNA from all the polymerases tested. Figure 10 illustrates the effect of the VsEndA_S44E treatment of Accustart and GoTaq polymerases. The VsEndA_S44E mutant has been shortened to "S44E" in the Figure legends. The level of contaminating bacterial DNA was reduced and spiked *E. coli* genomic DNA was removed. There is no or minimal impairment of the polymerase function after VsEndA_S44E treatment.

EXAMPLE 10 - Removal of contaminating DNA from a PCR master mix

Commercial quantitative PCR (qPCR) master mixes have been shown to contain trace amounts of contaminating bacterial genomic DNA. In this Example the ability of VsEndA_S44E to remove bacterial genomic DNA contaminants from commercial qPCR master mixes was tested. Maxima qPCR master mix (Fermentas) or Express qPCR Supermix Universal (Invitrogen) was treated with 25 U/µL VsEndA_S44E for 15 minutes at 37 °C. S44E_End I was inactivated by adding 10 mM DTT (1-4 dithiothreitol) and incubating at 40 °C for 30 minutes. To test for the effect of the VsEndA_S44E treatment on the removal of contaminating DNA from the polymerase, one S44E_End I treated sample was analysed alongside the following controls: a) samples containing buffer instead of VsEndA_S44E, b) samples where *E. coli* genomic DNA was added before buffer, c) samples where *E. coli* genomic DNA was added after buffer, d) samples where *E. coli* genomic DNA was added before VsEndA_S44E inactivation, and e) samples where *E. coli* genomic DNA was added after VsEndA_S44E inactivation. Finally, primers and probe were added to a final concentration of 300 nM and 200 nM respectively. The primers and probe were targeted to the 16S rRNA gene of *E. coli* as described by Corless *et al* (J Clin Microbiol. 2000, **38**(5):1747-52). The thermal cycling conditions were as follows: 50 °C for 2 min, 95 °C for 10 min followed by 45 cycles of 95 °C for 30 seconds, 60 °C for 30 seconds and 72 °C for 30 seconds. The qPCR was performed in 20 µl reactions in a Stratagene Mx3500P (Agilent technologies).

As illustrated in Figure 11, VsEndA_S44E is able to decrease the level of contaminating genomic bacterial DNA in Maxima qPCR master mix. The

VsEndA_S44E mutant has been shortened to "S44E" in the Figure legends. Furthermore, the addition of VsEndA_S44E to a master mix spiked with *E. coli* DNA results in the same QC-value as a VsEndA_S44E treated (non-spiked) master mix. S44E_End I is also able to remove some of the bacterial DNA contaminants contained in the master mix. The polymerase-reaction is not influenced by the VsEndA_S44E treatment. Thus, VsEndA_S44E is able to remove contaminating DNA, can be completely inactivated and the inactivated VsEndA_S44E does not impair the performance of the polymerase. Similar results were obtained with Express qPCR Supermix Universal (Life Technologies) (data not shown).

EXAMPLE 11 - Removal of bacterial genomic DNA from polymerase solutions of high salinity

VsEndA_S44E treatment is particularly useful in purifications of proteins that must be free of nuclease activity as inactivation of VsEndA_S44E easily can be accomplished. Furthermore, in the purification of DNA-binding proteins, the use of a salt active nuclease is convenient as salt can be added to protein preparations to limit DNA-protein interactions. In this Example we tested the ability of VsEndA_S44E to remove DNA contaminations from a DNA polymerase in a solution of 0.5 and 1.0 M sodium chloride.

TEMPase Hot Start DNA Polymerase (VWR) in 25 mM Tris-HCl, 5 mM $MgCl_2$ and 0.5 M or 1.0 M NaCl were treated with 25 U/µL VsEndA_S44E for 15 minutes at 37 °C. The following controls were analysed alongside the above sample: a) samples containing buffer instead of VsEndA_S44E, b) samples where 20 pg *E. coli* genomic DNA was added before buffer, and c) samples where 20 pg *E. coli* genomic DNA was added before VsEndA_S44E inactivation. VsEndA_S44E was inactivated by adding 10 mM DTT and incubating at 40 °C for 30 minutes. After the inactivation step the buffer of the samples were changed to a polymerase-buffer by using Zeba™Spin Desalting Columns with a cutoff of 7K (Thermo Scientific) according to the manufacturer's instructions. Finally primers and probe were added and the constituents of the polymerase buffer were as follows: 10 mM Tris-HCl, 20 mM KCl, 5 mM $MgCl_2$, 100 µM dATP, dCTP, dGTP and 200 µM dUTP, 300 nM of each primer and 200 nM of the probe. The thermal cycling conditions were as follows: 95 °C for 15 min followed by 45 cycles of 95 °C for 30 seconds and 60 °C for 30 seconds. The qPCR was performed in 20 µL reactions in a Stratagene Mx3500P (Agilent technologies).

Figure 12 illustrate the VsEndA_S44E treatment in polymerase solutions containing 0.5 M and 1.0 M sodium chloride. The VsEndA_S44E mutant has been shortened to "S44E" in the Figure legends. These Figures show that the VsEndA_S44E mutant's ability to remove the spiked *E. coli* DNA from the polymerase solution was not affected by the high salinity.

In a separate study, the activity of the VsEndA_S44E mutant was assessed over a range of differing sodium chloride and potassium chloride concentrations. Figure 14 illustrates that VsEndA_S44E has an optimum activity at about 0.5 M sodium chloride, but operates at a broad range of sodium chloride and potassium chloride concentrations.

In a further study, the enzymatic activity of the VsEndA_S44E mutant in degrading calf thymus DNA at a range of varying sodium chloride concentrations and pH levels was compared to the activity of commercially available Benzonase (*Serratia marcescens*) nuclease. Figure 16 illustrates that VsEndA_S44E degrades DNA at a broader range of pH levels and sodium chloride concentrations compared to Benzonase.

In a further study, the enzymatic activity of the VsEndA_S44E mutant in degrading DNA from *E. coli* cell lysate at a range of varying sodium chloride concentrations was assessed. Figure 17 illustrates that the VsEndA_S44E mutant was active at sodium chloride concentrations of 0.25 M to 1.0 M.

EXAMPLE 12 - Use of S44E EndA to remove DNA from a protein purification preparation

As VsEndA_S44E could be useful in protein purification schemes, particularly in the purification of DNA-binding proteins which must be free of nuclease activity and contaminating DNA, we tested the ability of VsEndA_S44E to remove genomic DNA from an *E. coli* extract containing a recombinantly expressed DNA-binding protein.

The recombinantly expressed protein in this Example was cod uracil-DNA glycosylase (cod UNG) which catalyzes the removal of uracil from uracil-containing DNA. *E. coli* cells containing the cod UNG were harvested, washed and then lysed by sonication in a Tris/HCl buffer (25 mM Tris/HCl pH 8.0, 10 mM NaCl, 1 mM EDTA,

1 % glycerol) containing lysozyme. The cell extract was centrifuged and the supernatant was collected. The pH of the supernatant was adjusted to 8.5 before the following concentrations of NaCl were added: 0 M, 0.25 M, 0.5 M, 0.75 M or 1.0 M. $MgCl_2$ was also added at 10 mM before treatment with 50 U/µL VsEndA_S44E for 30 min at 37 °C. VsEndA_S44E was then inactivated by adding 10 mM DTT and incubating at 40 °C for 30 min. Non-treated controls were also included. VsEndA_S44E treated supernatant (1 µL) was added in a 50 µl qPCR reaction containing TEMPase Hot Start DNA Polymerase (VWR) with the same PCR buffer composition and thermal cycling conditions as described earlier in Example 10.

As shown in Figure 13, VsEndA_S44E was able to remove most of the genomic *E. coli* DNA (>99.5 %) in samples containing 0.5 M NaCl or more, although a significant amount of DNA is still left in the lysate. In samples of relatively low salinity (0 M and 0.25 M NaCl), the Cq values are found to be the same for both the untreated and the VsEndA_S44E-treated samples. This suggests that the DNA within the sample is interacting with the protein, making it unavailable to both the VsEndA_S44E enzyme and the polymerase. In comparison, at higher NaCl concentrations (0.5 M, 0.75 M and 1.0 M) a clear difference in DNA levels is seen between the untreated samples and the samples containing the VsEndA_S44E mutant, suggesting that the NaCl make the DNA more available to both the VsEndA_S44E and the polymerase. This example demonstrates that VsEndA_S44E is ideal for removal of DNA from cell extracts containing recombinantly expressed DNA-binding proteins. The addition of salts reduces protein-DNA interactions making the DNA available for the salt-active VsEndA_S44E. Furthermore, VsEndA_S44E can easily be irreversibly inactivated, a feature which is important as preparations of DNA-binding proteins commonly need to be free of nuclease-activity.

EXAMPLE 13 - The effect of the inactivation additive TCEP on PCR quality

In this Example, we show the effect of TCEP on Tempase polymerase and Tempase Key buffer on PCR efficiency.

TCEP of varying concentrations were added to the PCR strips, before the rest of the PCR components were added. E. coli gDNA (100 fg) was used as template for a 23S primer/probe set. All samples were run in duplicates, and all qPCR reactions had a total volume of 20 µl. Tempase polymerase (VWR) in Tempase Key buffer and in "Arctic buffer" (final conc: 10 mM Tris HCl pH 8.3, 10 mM KCl and 5 mM

$MgCl_2$) was tested, as well as the Agilent Brilliant III mastermix (Agilent Technologies).

The results from this study show that a TCEP concentration of 2.5 mM or below has no noticeable effect on PCR efficiency (data not shown).

EXAMPLE 14 - Stability of VsEndA_S44E inactivation in Taq polymerase cleanups

The presence of TCEP may be necessary for keeping VsEndA_S44E inactive after inactivation procedures have been carried out. For this reason, we assessed the long term ability of TCEP to maintain the inactivation of VsEndA_S44E.

A buffer comprising 2 µL Tempase Key buffer, 0.8 µL dNTP/dUTP (2.5/5 mM), 0.2 µL Tempase (5 U/ µL), 1 µL VsEndA_S44E storage-buffer/ VsEndA_S44E (10 U/µL) and 1 µL water was mixed in a 17.5 x volume and incubated at 37 °C for 25 minutes. After the DNA decontamination step VsEndA_S44E was inactivated by adding 1 µL 50 mM TCEP per 1x rx and incubating at 37 °C for 25 minutes. After inactivation, the mix were stored for 14 days at 4 °C (at an effective concentration of 8.3 mM TCEP). The treated mix was thereafter dispersed in qPCR strips and added *E. coli* 23S primers/probe and template (200 fg *E. coli* gDNA or no template) dissolved in 14 µL. The total volume of each qPCR mix was 20 µL. This dilution ensured that the concentration of TCEP was reduced to 2.5 mM, which, from the results of Example 13, was known not to affect PCR efficiency. The strips were stored at 4 °C for 4 hours in order to detect any loss of template caused by reactivated VsEndA_S44E before the qPCR was run. The qPCR was performed in a Stratagene Mx3500P (Agilent technologies) and the thermal cycling conditions were as follows: 50 °C for 2 minutes, 95 °C for 10 minutes followed by 45 cycles of 95 °C, 60 °C for 30 seconds and 72 °C for 30 seconds.

The results show that there is no significant reactivation of VsEndA_S44E over a period of at least 2 weeks at 4 °C when stored in presence of the inactivation additive TCEP at a concentration of 8.3 mM (data not shown).

EXAMPLE 15 - The performance of a blend of VsEndA_S44E and VcEndA (wild-type) in buffers with varying sodium chloride concentrations and pHs

VsEndA_S44E has a pH-optimum of 8.5 and a sodium chloride concentration -optimum of 425 mM. A homologue of the wild-type *Vibrio salmonicida*-derived endonuclease (VsEndA) obtained from *Vibrio cholerae*, here referred to as VcEndA,

has a broad pH range, with a pH optimum of 7.5 and a sodium chloride concentration-optimum of 175 mM. We therefore combined VsEndA_S44E and VcEndA in order to determine whether it would result in a nuclease product with a broad pH and sodium chloride concentration working range, together with favourable inactivation characteristics. Here we tested the performance of this enzyme composition in Tris-buffers with varying pHs and sodium chloride concentrations against the performance of Benzonase, the leading non-specific nuclease on the market.

A total of twenty 25 mM tris-buffers containing 5 mM $MgCl_2$ were made with combinations of different pHs and sodium chloride concentrations as depicted in the matrix shown Table 6.

	0 M NaCl	0.25 M NaCl	0.5 M NaCl	0.75 M NaCl	1.0 M NaCl
pH 7	1	2	3	4	5
pH 7.5	6	7	8	9	10
pH 8.0	11	12	13	14	15
pH 8.5	16	17	18	19	20

Table 6

The blend of VsEndA_S44E and VcEndA was made by mixing the enzymes 1:1 (w/w) and the activity was measured in a 25 mM Tris-HCl-buffer pH 8 containing 250 mM sodium chloride. In 100 µL buffer containing 50 µg calf thymus DNA, 300 U enzyme was added and the reactions were incubated at 37 °C for 30 minutes. The reactions were stopped by adding an EDTA-containing loading dye and the samples were loaded on a 1 % agarose-gel.

The results showed no significant deterioration of VsEndA_S44E/VcEndA composition activity at a sodium chloride concentration range of between 0 M and 1 M. In comparison, Benzonase showed some loss in activity at 0.25 M and above (data not shown). In addition, a composition comprising VsEndA_S44E and VcEndA showed complete inactivation after storage with 20 mM DTT or TCEP at 4 °C for 6 hours, whilst a composition comprising wild-type VsEndA and VcEndA did not show similar inactivation characteristics under these conditions (data not shown).

CLAIMS

1. An endonuclease I or enzymatically active fragment thereof wherein said endonuclease I has the sequence of SEQ ID No. 4 or a sequence which is at least 70% identical thereto and wherein the amino acid residue which is immediately N-terminal of the FYCGC pentapeptide motif has been substituted with a residue which is negatively charged.

2. The endonuclease I or enzymatically active fragment thereof of claim 1, wherein said negatively charged residue is selected from the group consisting of glutamic acid, aspartic acid, 4-Fluoro-DL-glutamic acid, γ-Carboxy-DL-glutamic acid and D-2-Aminoadipic acid.

3. The endonuclease I or enzymatically active fragment thereof of claim 2, wherein said negatively charged residue is glutamic acid.

4. The endonuclease I or enzymatically active fragment thereof of any one of claims 1 to 3 which is derived from *Vibrio salmonicida*.

5. The endonuclease I or enzymatically active fragment thereof of any one of claims 1 to 4 which is substantially inactivated when incubated for 30 minutes at 50 °C in the presence of 0.5 mM TCEP and residual activity is assessed in the presence of 0.5 mM TCEP.

6. The endonuclease I or enzymatically active fragment thereof of any one of claims 1 to 5 which, at a concentration of 0.5 M sodium chloride, has a catalytic activity that is no less than 60% of the catalytic activity exhibited by said endonuclease I or enzymatically active fragment at its optimum salt concentration.

7. A method of removing contaminating polynucleotides from a sample, said method comprising contacting the sample with an endonuclease I or enzymatically active fragment thereof as defined in any one of claims 1 to 6.

8. The method of claim 7 wherein the sample is contacted with the endonuclease I or enzymatically active fragment thereof under conditions which permit digestion of any polynucleotide therein and then the sample and

endonuclease mixture are contacted with an inactivation additive at a temperature and for a time sufficient to inactivate said endonuclease.

9. The method of claim 7 or claim 8, wherein said sample is a preparation containing a recombinantly produced protein of interest, preferably said protein is an enzyme.

10. The method of claim 7 or claim 8, wherein said sample contains an analyte protein of interest.

11. The method of claim 10 wherein the sample is derived from a cell lysate, tissue sample or body fluid.

12. The method of claim 7 or claim 8, wherein the sample comprises an antibody or antibody fragment.

13. The method of claim 7 or claim 8, wherein the sample comprises a DNA binding protein or a protein which associates with nucleic acids in solution.

14. The method of claim 7 or claim 8, wherein the sample is a reagent solution that may be used in a polynucleotide analysis technique, preferably PCR or DNA/RNA sequencing.

15. The method of any one of claims 8 to 14 wherein the inactivation additive is a metal ion chelating agent or a disulphide bond reducing agent.

16. The method of claim 15 wherein the agent is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA) dithiothreitol (DTT), 2-mercaptoethanol, 2-mercaptoethylamine·HCl, TCEP (Tris(2-Carboxyethyl) phosphine) and N-ethylmaleimide.

17. A nucleic acid molecule encoding the endonuclease I or enzymatically active fragment thereof as defined in any one of claims 1 to 6 or encoding a protein comprising said endonuclease I or enzymatically active fragment thereof.

18. A method for the isolation and purification of the endonuclease I or enzymatically active fragment thereof as defined in any one of claims 1 to 6, said

method comprising expressing said endonuclease or fragment thereof in a suitable host cell, and subsequently separating the endonuclease from said host cells and/or the media in which said cells have been cultured.

19. A composition comprising the endonuclease I or enzymatically active fragment thereof of any one of claims 1 to 6 and a second endonuclease I or enzymatically active fragment thereof.

20. The composition of claim 19 wherein the second endonuclease I or enzymatically active fragment thereof has the sequence of SEQ ID No. 5 or a sequence which is at least 80% identical thereto.

21. The composition of claim 20 wherein the second endonuclease I or enzymatically active fragment thereof is from *Vibrio cholerae*.

Figure 1

```
VsEndA      MKLIRLVISLIAVSFTVNVMAAPPSSFSKAKKEAVKIYLDYPTSFYCGCDITWKNKKKGI 60
VcEndA      MMIFRFVTT-LAASLPLLTFAAP-ISFSHAKNEAVKIYRDHPVSFYCGCEIRWQGKK-GI 57
            *   * *    * *      ***  *** ** ****** * * ****** * *  ** **

VsEndA      PELESCGYQVRKQEKRASRIEWEHVVPAWQFGHQRQCWQKGGRKNCTRNDKQFKSMEADL 120
VcEndA      PDLESCGYQVRKNENRASRIEWEHVVPAWQFGHQLQCWQQGGRKNCTRTSPEFNQMEADL 117
            * ********** * ****************** **** ********    *  *****

VsEndA      HNLVPAIGEVNGDRSNFRFSQWNGSKGAFYGQCAFKVDFKGRVAEPPAQSRGAIARTYLY 180
VcEndA      HNLTPAIGEVNGNRSNFSFSQWNGIDGVTYGQCEMQVNFKERTAMPPERARGAIARTYLY 177
            *** ******** **** ******  *  ****   * ** * * **   **********

VsEndA      MNNEYKFNLSKAQRQLMEAWNKQYPVSTWECTRDERIAKIQGNHNQFVYKACTK 234
VcEndA      MSEQYGLRLSKAQNQLMQAWNNQYPVSEWECVRDQKIEKVQGNSNRFVREQCPN 231
            *   *   ***** *** *** ***** *** **  * * *** * **   *
```

Figure 2

```
1     ATG AAA TTA ATT CGC TTA GTT ATC AGT CTT ATT GCT GTC AGT TTC   45
1      M   K   L   I   R   L   V   I   S   L   I   A   V   S   F    15

46    ACT GTT AAC GTA ATG GCA GCA CCT CCT TCT TCT TTC TCA AAA GCA   90
16     T   V   N   V   M   A   A   P   P   S   S   F   S   K   A    30

91    AAA AAA GAA GCC GTC AAA ATC TAT CTT GAT TAC CCA ACC GAG TTT 135
31     K   K   E   A   V   K   I   Y   L   D   Y   P   T   E   F    45

136   TAT TGT GGC TGT GAC ATT ACG TGG AAA AAT AAA AAG AAA GGG ATC   180
46     Y   C   G   C   D   I   T   W   K   N   K   K   K   G   I    60

181   CCT GAA TTA GAA AGC TGC GGA TAC CAA GTC CGT AAA CAA GAA AAA   225
61     P   E   L   E   S   C   G   Y   Q   V   R   K   Q   E   K    75

226   CGA GCC AGT CGT ATT GAA TGG GAG CAT GTT GTT CCA GCA TGG CAA   270
76     R   A   S   R   I   E   W   E   H   V   V   P   A   W   Q    90

271   TTT GGT CAT CAA CGT CAA TGT TGG CAA AAA GGT GGG CGT AAA AAT   315
91     F   G   H   Q   R   Q   C   W   Q   K   G   G   R   K   N   105

316   TGC ACT AGA AAC GAC AAG CAA TTC AAA TCA ATG GAA GCC GAC TTA   360
106    C   T   R   N   D   K   Q   F   K   S   M   E   A   D   L   120

361   CAT AAT CTA GTG CCT GCG ATT GGT GAA GTA AAC GGG GAC AGA TCC   405
121    H   N   L   V   P   A   I   G   E   V   N   G   D   R   S   135

406   AAC TTC CGA TTC TCA CAA TGG AAT GGA AGC AAA GGC GCT TTC TAT   450
136    N   F   R   F   S   Q   W   N   G   S   K   G   A   F   Y   150

451   GGC CAA TGT GCT TTT AAA GTC GAC TTC AAA GGC CGT GTT GCC GAG   495
151    G   Q   C   A   F   K   V   D   F   K   G   R   V   A   E   165

496   CCA CCA GCA CAA TCT CGT GGT GCC ATT GCC CGA ACG TAT CTT TAT   540
166    P   P   A   Q   S   R   G   A   I   A   R   T   Y   L   Y   180

541   ATG AAC AAC GAA TAT AAA TTT AAC TTA TCA AAA GCA CAG CGA CAA   585
181    M   N   N   E   Y   K   F   N   L   S   K   A   Q   R   Q   195

586   CTT ATG GAA GCA TGG AAC AAA CAG TAT CCA GTA TCA ACT TGG GAA   630
196    L   M   E   A   W   N   K   Q   Y   P   V   S   T   W   E   210

631   TGT ACT CGT GAT GAA CGT ATA GCA AAA ATC CAA GGC AAT CAT AAT   675
211    C   T   R   D   E   R   I   A   K   I   Q   G   N   H   N   225

676   CAA TTT GTT TAT AAA GCA TGC ACT AAA TAA   705
226    Q   F   V   Y   K   A   C   T   K   *
```

Figure 3


V.salmonicida ----------AP--PSSFSKAKKEAVKIYLDYPT------SFYCGCDITWKNKKKGIP 40
V.cholerae ----------A--PISFSHAKNEAVKIYRDHPV------SFYCGCEIRWQGKK-GIP 38
Oceanimonas sp. ----------GE--AMSFRQAKKVAPGIYNDNLK------TFYCGCNIDTQGKK-LVP 39
Salmonella sp. ----------DG--INNFSQAKAASVKVNADAPG------SFYCGCQIRWQGKK-GVV 39
Enterobacter sp.----------DG--INSFSQAKAAGVKVNADVPG------DFYCGCKINWQGKK-GIV 39
Yokenella sp. ----------EG--INSFSQAKAAGVKVNADVAG------DFYCGCKINWQGKK-GVV 39
Klebsiella sp. ----------AG--INSFSQAKAAGVKVNADVPG------DFYCGCKIDWQGKK-GVI 39
E.coli ----------EG--INSFSQAKAVAVKIHADAPG------TFYCGCKIDWQGKK-GVV 39
Shigella sp. ----------EG--INSFSQAKAAAVKVHADAPG------TFYCGCKINWQGKK-GVV 39
Citrobacter sp. ----------EG--INSFSQAKAAGVKVNADAPG------DFYCGCKINWQGKK-GVV 39
Cronobacter sp. ----------ASG--IHSFSQAKAAGVKINADAPG------DFYCGCPITWQGKK-GIP 40
Rahnella sp. IGALVPLSAFSQSGNTINNFSQAKAAAVKINQGAP-------TFYCGCNIRWQGKK-GTP 52
Erwinia sp. -FPPLFCHALSQGNYQQNNFSQAKAWAAQIHHDAPG------TFYCGCKIDWQGKK-GVP 52
Yersinia sp. ----------HG--INNFSQAKAVAAKIHQDAPG------SFYCGCQIDWQGKK-GIP 39
Serratia sp. ----------HG--INNFSQAKAAAAKINQDAPG------SFYCGCKINWHGKK-GLP 39
Pseudomonas sp. ----------AQAQAPRTFSEAKKVAWGLYAPQST------EFYCGCKY--TGKR---V 38
V.salmonicida ELESCGYQVRKQEKRASRIEWEHVVPAWQFGHQRQCWQKGGRKNCTRNDKQFKSMEADLH 100
V.cholerae sp. DLESCGYQVRKNENRASRIEWEHVVPAWQFGHQLQCWQQGGRKNCTRTSPEFNQMEADLH 98
Oceanimonas sp. DLAGCGYQVRKQQQRASRIEWEHVVPAWEFGHQRQCWQQGGRKNCTRKDELFRQMEGDLH 99
Salmonella sp. DLESCGYKVRKNENRARRIEWEHVVPAWQFGHQRQCWQDGGRKNCAK-DPVYRKMESDMH 98
Enterobacter sp.DLESCGYKVRKNENRASRIEWEHVVPAWQFGHQRQCWQDGGRKNCAK-DPVYRQMESDMH 98
Yokenella sp. DLESCGYKVRKNENRASRIEWEHVVPAWQFGHQRQCWQDGGRKNCGK-DPVYRQMESDMH 98
Klebsiella sp. DLESCGYKVRKNENRASRVEWEHVVPAWQFGHQRQCWQEGGRKNCAK-DPEYRKMESDMH 98
E.coli DLQSCGYQVRKNENRASRVEWEHVVPAWQFGHQRQCWQDGGRKNCAK-DPVYRKMESDMH 98
Shigella sp. DLQSCGYQVRKNENRASRVEWEHVVPAWQFGHQRQCWQDGGRKNCAK-DPVYRKMESDMH 98
Citrobacter sp. DLESCGYKVRKNENRASRIEWEHVVPAWQFGHQRQCWQDGGRKNCAK-DPVYRKMESDMH 98
Cronobacter sp. DLKACGYQVRKNENRASRIEWEHVVPAWQFGHQRQCWQNGGRKNCDK-DPVYREMETDLH 99
Rahnella sp. DLQSCGYAVRKSELRASRIEWEHVVPAWQFGHQMQCWQDGGRKNCAK-NADYRQVETDLH 111
Erwinia sp. DLTSCGYQVRKNSERASRIEWEHVVPAWSFGHQRQCWQDGGRKNCVK-DPVYRRMESDLH 111
Yersinia sp. DLNSCGYQPRKNAARAARIEWEHVVPAWQFGHQRQCWQQGGRKNCAK-DPVYRQIETDLH 98
Serratia sp. DLNACGYQPRKNAQRAGRIEWEHVVPAWQFGHQLQCWQDGGRKNCNR-DPVYRQIETDLH 98
Pseudomonas sp. DLAGCGYVPRKSAKRASRIEWEHIVPAWQIGHLRQCWQNGGRKNCTKSDPVYKRAEADLH 98
V.salmonicida NLVPAIGEVNGDRSNFRFSQWNGSKGAFYGQCAFKVDFKGRVAEPPAQSRGAIARTYLYM 160
V.cholerae NLTPAIGEVNGNRSNFSFSQWNGIDGVTYGQCEMQVNFKERTAMPPERARGAIARTYLYM 158
Oceanimonas sp. NLVPAVGEVNGDRSNYRFSEWNG-KPVQYGQCQMLVDFKGRKVQPPEQSRGAIARTYLYM 158
Salmonella sp. NLQPAIGEVNGDRGNFMYSQWNG-GEGQYGQCAMKVDFKAKLAEPPARARGAIARTYFYM 157
Enterobacter sp.NLQPAVGEVNGDRGNFMYSQWNG-GEGQYGQCGMKVDFKEKVAEPPARARGSIARTYFYM 157
Yokenella sp. NLQPAVGEVNGDRGNFMYSQWNG-GEGQYGQCAMKVDFKGKVAEPPARARGAIARTYFYM 157
Klebsiella sp. NLQPAVGEVNGDRGNFMYSQWNG-GEGQYGQCTMKVDFKDKIAEPPARARGAIARTYFYM 157
E.coli NLQPSVGEVNGDRGNFMYSQWNG-GEGQYGQCAMKVDFKEKVAEPPARARGAIARTYFYM 157
Shigella sp. NLQPSVGEVNGDRGNFMYSQWNG-GEGQYGQCAMKVDFKEKAAEPPARARGAIARTYFYM 157
Citrobacter sp. NLQPAVGEVNGDRANFMYSQWNG-GEGQYGQCAMKVDFKEKVAEPPARARGAIARTYFYM 157
Cronobacter sp. NLQPAVGEVNGDRGNFLYSQWRG-GEGQYGQCEMKVDFKNKQAEPPARARGAIARTYFYM 158
Rahnella sp. NLEPAIGEVNGDRNNFMYSQWNG-GEGQYGRCEMKIDFKAKAAEPPARARGAIARTYFYM 170
Erwinia sp. NLQPAIGEVNGDRGNFMYGQWSG-GEQQYGQCAMKVDFKNKLAEPPARARGAIARTWFYM 170
Yersinia sp. NLQPAIGEVNGDRNNFMYSQWNG-GSGQYGQCAMKVDFKNKLAEPPVRARGAIARTYFYM 157
Serratia sp. NLQPAIGEVNGDRNNFMYSQWRG-GEGQYGQCPMKVDFKHKQAEPPARARGAIARTYFYM 157
Pseudomonas sp. NLVPSIGEVNGDRSNFSFGWVPE-QKGQYGSCLTQVDFKAKKVMPRPSIRGMIARTYFYM 157

Figure 3 (cont)

```
V.salmonicida    NNEYKFNLSKAQRQLMEAWNKQYPVSTWECTRDERIAKIQGNHNQFVYKACTK------- 213
V.cholerae       SEQYGLRLSKAQNQLMQAWNNQYPVSEWECVRDQKIEKVQGNSNRFVREQCPN------- 211
Oceanimonas sp.  QQQYRLKIARQQQKLFEAWNRQYPASPWECERDNRISRIQGNHNPFVQEQCKNYAYTPNP 218
Salmonella sp.   RDQYQLKLSRQQTQLFNVWDKQYPVTAWECERDARIAKVQGNHNPYVQRACQARKS---- 213
Enterobacter sp. RDRYNLNLSRQQTQLFNAWNKQYPVTEWECQRDERIARVQGNHNPYVQRACQAQKS---- 213
Yokenella sp.    RDRYQLALSRQQTQLFNAWDKQYPVSEWECERDERIAKYQGNHNPYVQRACQAQKS---- 213
Klebsiella sp.   RDRYQLNLSRQQTQLFTAWNKQYPVTAWECERDERIAKVQGNHNPYVQQACQAQKS---- 213
E.coli           RDQYNLTLSRQQTQLFNAWNKMYPVTDWECERDERIAKVQGNHNPYVQRACQARKS---- 213
Shigella sp.     RDQYNLTLSRQQTQLFNAWNKMYPVTDWECERDERIAKVQGNHNPYVQRACQARKS---- 213
Citrobacter sp.  RDQYSLTLSRQQTQLFNAWNKQYPVTDWECERDERIAKVQGNHNPYVQRACQAQKS---- 213
Cronobacter sp.  RDKYQLNLSRAQTQLFEAWNKLYPVTPWECTRDERIAKVQGNHNPYVQQACQGQNR---- 214
Rahnella sp.     RDQYKLNLSRQQTQLFTAWDRQYPVTAWECERDNRIARVQGNHNPYVQQACAQRKS---- 226
Erwinia sp.      RDQYQLSMSKQQTQLMTAWSKLYPVTPWECERDRRIARVQGNHNPYVQQACQR------- 223
Yersinia sp.     RDQYQLRLSSQQSKLFGVWDRQYPVTDWECLRDERIAKTQGNHNPYVQRACQRPKS---- 213
Serratia sp.     RDRYHLRLSRQQTQLFEVWNRQYPVSQWECQREARIAKVQGNRNPYIQQACQRQKG---- 213
Pseudomonas sp.  SKQYNLRLSRQDQQLYQAWDKTYPPQIWERQRNQQVACVMGRGNEFVGPVDLKACK---- 213
                              *   *   **    *  *        *  *
```

Figure 4


V.salmonicida APPSSFSKAKKEAVKIYLDYPTSFYCGCDITWKNKKKGIPELESCGYQVRKQEKRASRIE 60
V.fischeri APPSSFSKAKKEAVKIYLDHPTSFYCGCDITWKDKKKGIPDLQSCGYNVRKQEKRASRIE 60
V.wodanis APPSSFSKAKKLAVKIYLDHPTSFYCGCDITWKDKKKGIPDLESCGYEVRKQEKRASRIE 60
V.splendidus APPSSFSKAKKEAVKIYLDHPTSFYCGCDITWKDKKKGIPDLDGCGYQVRKQQKRASRIE 60
V.cholerae -APISFSHAKNEAVKIYRDHPVSFYCGCEIRWQGKK-GIPDLESCGYQVRKNENRASRIE 58
V.harveyi APPSSFSAAKREAVKIYADHPTSFYCGCDIKWQGKK-GIPDLASCGYQVRKQEKRASRIE 59
V.rotiferianus APPSSFSAAKREAVKIYADHPTSFYCGCDIKWQGKK-GVPDLASCGYQVRKQEKRASRIE 59
V.tubiashii APPSSFSKAKKEAVKIYADHPTSFYCGCNISWQGRK-GIPDLESCGYQVRKQQKRASRIE 59
V.sinaloensis APPSSFSKAKKEAIKIYADHPSSFYCGCDITWQGRK-GTPDLNSCGYQVRKQEKRASRIE 59
V.vulnificus APPSSFSAAKQQAVKIYQDHPISFYCGCDIEWQGKK-GIPNLETCGYQVRKQQTRASRIE 59
V.furnissii -APASFSQAKREAVKIYQDHPVTFYCGCDIQWQGKK-GTPDLKGCGYQVRKQEKRASRIE 58
V.anguillarum APPASFSQAKKEALKIYHDHPVSFYCGCDIAWQGKK-GTPDLQACGYQVRKQQTRASRIE 59
WEHVVPAWQFGHQRQCWQKGGRKNCTRNDKQFKSMEADLHNLVPAIGEVNGDRSNFRFSQ 120
WEHVVPAWQFGHQRQCWQDGGRKNCTRKDKQFKLMEADLHNLVPAIGEVNGDRSNFRFSQ 120
WEHVVPAWQFGHQRQCWQDGGRKNCTKNDKNFKMMEADLHNLVPAIGEVNGDRSNFRFSQ 120
WEHVVPAWQFGHQRQCWQDGGRKNCTRNDKVFKSMEADLHNLTPAIGEVNGDRSNYNFSQ 120
WEHVVPAWQFGHQLQCWQQGGRKNCTRTSPEFNQMEADLHNLTPAIGEVNGNRSNFSFSQ 118
WEHVVPAWQFGHQRQCWQNGGRKNCTRNDNVFKSMEADLHNLTPAIGEVNGDRSNYNFSQ 119
WEHVVPAWQFGHQRQCWQNGGRKNCTRNDKVFKSMEADLHNLTPAIGEVNGDRSNYNFSQ 119
WEHVVPAWQFGHQRQCWQNGGRKNCTKNDKAFRMMEADLHNLTPAIGEVNGDRSNYNFSQ 119
WEHVVPAWQFGHQRQCWQNGGRKNCSKNDNVFRSMEADLHNLTPAIGEVNGDRSNYNFSQ 119
WEHVVPAWQFGHQRQCWQKGGRKNCSKNDQQFRLMEADLHNLTPAIGEVNGDRSNFNFSQ 119
WEHVVPAWQFGHQLQCWQQGGRKQCSRHDTAFKRMEADLHNLTPAIGEVNGDRSNLNFSQ 118
WEHVVPAWQFGHQRQCWQQGGRKNCTKNDTIFRSMEADLHNLTPAIGEVNGDRSNYNFSQ 119
WNGSKGAFYGQCAFKVDFKGRVAEPPAQSRGAIARTYLYMNNEYKFNLSKAQRQLMEAWN 180
WNGNKGAYYGQCAFKVDFKGRVAEPPAQSRGAIARTYLYMNQEYRFNLSKSQRQLMNAWD 180
WNGSKGANYGQCAFKVDFKGRVAEPPAQSRGAIARTYMYMNKEYRFNLSKAQRQLMEAWD 180
WNSMDGVSYGQCEMQVNFKQRKVMPPDRAKGSIARTYLYMSQEYGFKLSKQQTNLMMAWN 180
WNGIDGVTYGQCEMQVNFKERTAMPPERARGAIARTYLYMSEQYGLRLSKAQNQLMQAWN 178
WNGMDGVSYGRCEMQVNFKQRKVMPPDRARGSIARTYLYMSKEYGFKLSKQQTQLMSAWN 179
WNGMDGVSYGRCEMQVNFKQRKVMPPDRARGSIARTYLYMSKEYGFKLSKQQTQLMSAWN 179
WNGIDGVSYGRCEMQVNFKHRKVMPPDRAKGSIARTYLYMSQEYGFRLSKQQTQLMNAWN 179
WNGVDGVSYGRCEMQVNFKQRKVMPPDRAKGSIARTYLYMSKEYGFKLSKQQTQLMTAWN 179
WNGMDGVSYGRCEMQVNFKQRKVMPPDRARGSIARTYLYMSQEYGFQLSKQQQQLMQAWN 179
WHGIDGATYGQCEIQVNFQQRKVMPPERARGAIARTYLYMSQEYGFRLSKSQTQLMQVWN 178
WNGVEGESYGRCEMQVDFKQRKVMPPDRARGSIARTYLYMSQNYGFQLSKSQTQLMQAWN 179
KQYPVSTWECTRDERIAKIQGNHNQFVYKACTK- 213
KQYPVSEWECERDKRIAKIQGNHNQFVYKACRK- 213
KQYPVSAWECERDQRIAKIQGNHNQFVFKACTK- 213
KQFPVNEWECTRDERIFAIQGNHNPFVYQACK- 212
NQYPVSEWECVRDQKIEKVQGNSNRFVREQCPN- 211
KSYPVDKWECERDERIAKIQGNHNPFVQEACRA- 212
KTYPVDKWECERDERIAKIQGNHNPFVQEACRA- 212
KQFPVDHWECEREQRIFKVQGNHNPFVHQACQAL 213
KQFPVDEWECERDKRIFKVQGNHNP--------- 204
KSYPVDEWECTRDDRIAKIQGNHNPFVQQSCTVR 213
RQYPVDSWECERDQRIFKVQGNHNPFVRQQCSS- 211
RQYPADEWECKRDQRIAKVQGNHNPFVQQQCRS- 212

Figure 5


Expression level in P. pastoris
45000
40000
35000
30000
25000
20000
15000
10000
5000
0
Activity (U/ml)
0
20
40
60
80
Time (h)
S44E
WT

Figure 6a



Figure 6b



Figure 7


50
40
30
20
10
0
Remaining activity (%)
0
10
20
30
40
50
Time (minutes)
S44E (1 mM TCEP)
S44E (1 mM b-me)
S44E (1 mM DTT)

Figure 8a



Figure 8b



Figure 8c



Figure 8d



Figure 9a



Figure 9b



Figure 10a



Figure 10b



Figure 11


Fluorescence (dRn)
1
0.1
0.01
15
20
25
30
35
40
45
Cycles
Non-treated (S44E-buffer).
S44E-treated.
Addition of E.coli DNA before incubation with S44E-buffer.
Addition of E.coli before treatment with S44E.
Addition of E.coli DNA after incubation with S44E-buffer.
Addition of E.coli after treatment with S44E.

Figure 12a



Figure 12b



Figure 13


Fluorescence (dR)
10000
1000
100
15
20
25
30
35
40
45
Cycles
0 M NaCl buffer
0 M NaCl S44E
0,25 M NaCl buffer
0,25 M NaCl S44E
0,5 M NaCl buffer
0,5 M NaCl S44E
0,75 M NaCl buffer
0,75 M NaCl S44E
1,0 M NaCl buffer
1,0 M NaCl S44E

Figure 14


100
80
60
40
20
0
% Relative activity
KCl
NaCl
0 M
0.25 M
0.5 M
0.75 M
1 M

Figure 15



Figure 16a



Figure 16b



Figure 17



INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2013/050387

A. CLASSIFICATION OF SUBJECT MATTER
INV. C12N9/22 C12N9/99 C12Q1/68
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, Sequence Search, WPI Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE UniProt [Online] 19 January 2010 (2010-01-19), "SubName: Full=Endonuclease I; EC=3.1.21.1;", XP002694179, retrieved from EBI accession no. UNIPROT:D0YWJ5 Database accession no. D0YWJ5 sequence ----- -/--	1,4,17, 18

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
20 March 2013	08/04/2013

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Wiame, Ilse

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE UniProt [Online] 3 May 2011 (2011-05-03), "SubName: Full=Extracellular deoxyribonuclease;", XP002694180, retrieved from EBI accession no. UNIPROT:F0LWL3 Database accession no. F0LWL3 sequence	1,4,17, 18
A	BJØRN ALTERMARK ET AL: "Structural adaptation of endonuclease I from the cold-adapted and halophilic bacterium Vibrio salmonicida", ACTA CRYSTALLOGRAPHICA SECTION D BIOLOGICAL CRYSTALLOGRAPHY, vol. 64, no. 4, 1 April 2008 (2008-04-01), pages 368-376, XP055057157, ISSN: 0907-4449, DOI: 10.1107/S0907444908000097 abstract; figure 2	1-21
A	WO 2011/010094 A1 (BIOTEC PHARMACON ASA [NO]; ELDE MORTEN [NO]; LANES OLAV [NO]; GJELLESV) 27 January 2011 (2011-01-27) cited in the application the whole document	1-21
A	VERONIKA E ANISIMOVA ET AL: "Thermolabile duplex-specific nuclease", BIOTECHNOLOGY LETTERS, SPRINGER NETHERLANDS, DORDRECHT, vol. 31, no. 2, 23 September 2008 (2008-09-23), pages 251-257, XP019639534, ISSN: 1573-6776 abstract page 255, column 1, line 1 - line 10	1-21
X,P	DATABASE UniProt [Online] 6 February 2013 (2013-02-06), "SubName: Full=Extracellular deoxyribonuclease Dns; EC=3.1.21.-;", XP002694181, retrieved from EBI accession no. UNIPROT:K8B9T0 Database accession no. K8B9T0 sequence	1,2,4, 17,18

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/GB2013/050387

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2011010094 A1	27-01-2011	AU 2010274809 A1	02-02-2012
		CA 2768593 A1	27-01-2011
		CN 102510904 A	20-06-2012
		EP 2456886 A1	30-05-2012
		GB 2474225 A	13-04-2011
		JP 2012533316 A	27-12-2012
		KR 20120058520 A	07-06-2012
		SG 178040 A1	29-03-2012
		US 2011020878 A1	27-01-2011
		WO 2011010094 A1	27-01-2011